Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Oxford Nanopore delivers 'strong' H1 performance, reported revenues up 25pc YOY

(Sharecast News) - Molecular technology business Oxford Nanopore said on Monday that it had delivered a "strong" first half performance, with reported revenues expected to be up by a quarter year-on-year. Oxford Nanopore H1 revenues of £105.0m, up 25% on a reported basis and 28% at constant currency, with growth being the strongest across its PromethION product range, up approximately 59% against FY24.

The FTSE 250-listed group said it had delivered strong growth in both research and applied markets, up by approximately 22% and 33%, respectively. On a geographical basis, the strong revenue performance was led by its Europe, Middle East, Africa & India unit and its Asia-Pacific operations, both up by more than 30% year-on-year at constant currency rates.

Oxford Nanopore also highlighted that targeted measures to improve gross margins progressed in line with expectations. However, these initiatives were offset in H1 by a non-cash one-off charge related to inventory alongside currency headwinds, resulting in a gross margin "marginally below" H124.

"The group continued to progress on its path to profitability, delivering a year-on-year and sequential reduction in adjusted EBITDA loss, supported by disciplined cost management and gross profit growth in the period," said Oxford Nanopore. "Full-year guidance remains on track, across all metrics, supported by strong first-half execution and continued momentum across the business."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.